About Aignostics
Aignostics is a Berlin and New York-based AI company transforming drug development and patient outcomes through advanced pathology analytics. As a spin-off from Charité Berlin, one of Europe's largest university hospitals, Aignostics has built industry-leading foundation models in collaboration with Mayo Clinic to analyze complex biomedical data at scale. The company's flagship product, Atlas H&E-TME, provides comprehensive tumor microenvironment profiling from H&E-stained whole slide images at single-cell resolution. Powered by Atlas 2, their latest foundation model co-developed with Mayo Clinic, the platform delivers over 4,500 quantitative metrics per image including cell detection and classification across 9 cell types, tissue segmentation into 7 regions, and spatial network analysis. The solution currently supports eight primary cancer types with validated performance on at least 90% of invasive morphological subtypes. Aignostics offers both products and custom services spanning target and biomarker discovery, translational research, and digital diagnostics. The company maintains proprietary access to pathology samples and multimodal data from over 30 million patients at leading university hospitals and laboratories. Their interdisciplinary team combines data scientists, machine learning engineers, pathologists, and biologists to deliver validated solutions for biopharma companies and academic researchers. The company is ISO 13485 and ISO 27001 certified with a GCP-ready clinical trial platform.
Mission & Story
Mission
Our mission is to transform drug development and improve patient outcomes with AI that delivers novel insights for precision medicine.
Founding Story
Aignostics is a spin-off from Charité Berlin, one of Europe's largest and most esteemed university hospitals. The company has grown from its academic roots to include offices in Berlin and New York with a diverse array of cross-functional experts.
Clinical Focus
Medical conditions and clinical areas addressed by Aignostics.
Who It Serves
Milestones & Awards
Recent Milestones
January 2026: Announced Atlas 2 foundation model with Mayo Clinic setting new performance standards. June 2026: Partnership with Pancreatic Cancer Action Network. Quarterly rollout of new cancer types for Atlas H&E-TME. Launched OpenTME dataset with analyzed TCGA whole-slide images.
Awards & Recognition
Recent awards mentioned but not specified on site
Key Partnerships
Social & Media
Company Details
- Headquarters
- Berlin, Germany
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.